Insurance claims analysis has shown that the use of the (CDC recommended) recombinant zoster vaccine (RZV) for prevention of herpes zoster was highly used in patients with immune-mediated inflammatory diseases and was safe, as higher rates of arthritis flares were not evident.
Dr. John Cush RheumNow
4 years 3 months ago
Watch: Fatigue and Central Sensitization in Rheumatic Disease -
We're sharing Philip Mease, MD presentation from the RheumNow Live 2022 meeting held in March.
https://t.co/SFzsszL1aM https://t.co/DkxVPim9iU
Dr. John Cush RheumNow
4 years 3 months ago
Learn how clinical research targeting immune pathways can help reduce the burden of #psoriaticarthritis symptoms, such as joint pain, stiffness, and swelling, as well as fatigue: https://t.co/ReBQVyYVka Sponsored by Janssen @JanssenUS https://t.co/fRb6kAj848
Dr. John Cush RheumNow
4 years 3 months ago
Study of interferon (IFN) gene signature (IGS) finds IGS elevated in half of early RA pts; high IGS portends higher DAS28, fewer EULAR good resp & higher IFN-α; the latter assoc w/ epigentic changes, more lymphoctye activation. IFN-α as a biomarker? https://t.co/BHC98OR30A https://t.co/SRE7KVaoha
Dr. John Cush RheumNow
4 years 3 months ago
Yesterday the FDA approved baricitinib (Olumiant) as the first systemic treatment for Alopecia Areata. Approval based on 2 DBRPCT Trial AA-1, AA-2) - 32% & 35% of pts on Bari 4 mg regrew scalp hair coverage by wk 36. https://t.co/SU74OxI2BC https://t.co/2wluug1fj4
There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question.
Dr. John Cush RheumNow
4 years 3 months ago
450 axSpA pts followed 2868 Pt-yrs, 48% on TNFis. TNFi Rx pts had reduced CV risk (HR 0.30; 0.10–0.85), but no longer signif after adjustment for CRP, ESR (HR 0.37, 0.12–1.12, p = 0.077). Reduced CV risk, may not be specifically due to TNFi use https://t.co/mVHYn3PteL https://t.co/bgKWreBL8z
A retrospective cohort study has shown that outcomes in pregnant systemic lupus erythematosus (SLE) patients has significantly improved in the last decade, but there still is a high risk of adverse pregnancy outcomes (APO).
A retrospective Danish SLE cohort was used to identify pregnancies in SLE patients from a single center between January 2010 and October 2020.
Dr. John Cush RheumNow
4 years 3 months ago
JAKi not yet safe in pregnancy - theyre fetotoxic at high doses (animals). JAKi do cross placenta. ACR Guidelines: no position due to no data. 47 tofa Rheum & 15 UC maternal exposures - no signif probs. Paternal use of JAKi is ok.
https://t.co/pom5KD0qt7 https://t.co/djYHZ5LdcE https://t.co/47lfyZC4H3
Dr. John Cush RheumNow
4 years 3 months ago
Watch: The Microbiome in Spondyloarthritis
Can microbes trigger SpA/PsA?
https://t.co/KN7dMFU9qo https://t.co/k3M5QfwqGp
